Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny Y Xue

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2020
Quest for Clinically Effective RAF Dimer InhibitorsJenny Y Xue, Piro Lito
Cancer Discovery|May 18, 2021
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant TumorsYulei Zhao, Jenny Y Xue, Piro Lito
Science (New York, N.Y.)|October 7, 2021
The G protein signaling regulator RGS3 enhances the GTPase activity of KRASChuanchuan Li, Alberto Vides, Dongsung Kim, et al.
Nature|January 10, 2020
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibitionJenny Y Xue, Yulei Zhao, Jordan Aronowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cell|June 11, 2019
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves ChemotherapyJessica L Wojtaszek, Nimrat Chatterjee, Javaria Najeeb, et al.
Nature|May 31, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growthDongsung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Cell Reports. Medicine|August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinomaMarie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Nature|November 11, 2021
Diverse alterations associated with resistance to KRAS(G12C) inhibitionYulei Zhao, Yonina R Murciano-Goroff, Jenny Y Xue, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2020
Quest for Clinically Effective RAF Dimer InhibitorsJenny Y Xue, Piro Lito
Cancer Discovery|May 18, 2021
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant TumorsYulei Zhao, Jenny Y Xue, Piro Lito
Science (New York, N.Y.)|October 7, 2021
The G protein signaling regulator RGS3 enhances the GTPase activity of KRASChuanchuan Li, Alberto Vides, Dongsung Kim, et al.
Nature|January 10, 2020
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibitionJenny Y Xue, Yulei Zhao, Jordan Aronowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cell|June 11, 2019
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves ChemotherapyJessica L Wojtaszek, Nimrat Chatterjee, Javaria Najeeb, et al.
Nature|May 31, 2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growthDongsung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Cell Reports. Medicine|August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinomaMarie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Nature|November 11, 2021
Diverse alterations associated with resistance to KRAS(G12C) inhibitionYulei Zhao, Yonina R Murciano-Goroff, Jenny Y Xue, et al.
Pageof 1